Manufactured by 3M Drug Delivery Systems, it is claimed to be the first bioequivalent alternative for GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate).
It can be used for the treatment or prevention of asthma symptoms in adults aged 18 years and above.
The inhaler offers the same ease of use expected by the patients from their asthma therapy, and will be available in two variants of – 125/25mcg and 250/25mcg – with 120 doses in the market.
Mylan president Rajiv Malik said: "Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline and further demonstrates our ability to successfully execute on one of our key strategic growth drivers."
Mylan Europe president Jacek Glinka said: "The launch of Mylan’s Sirdupla broadens patient access to an important treatment option and offers a familiar pMDI device experience to UK asthma sufferers.
"Asthma is a widespread illness in the UK and we are committed to contributing to ease this burden to both patients and the NHS."
The European nation is one of those having the highest rates of asthma in the continent, with one in five households being affected by it. On an average, the disease is the reason behind three deaths in the UK every day.
Nearly 5.4 million people suffer from asthma in the country, which costs the National Health Service (NHS) £1bn on an yearly basis.
3M Drug Delivery Systems president and general manager Cindy Kent said: "3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK.
"By partnering with Mylan, 3M has taken an important step forward in the generics space.
"This partnership combines 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market, including expertise in commercializing complex respiratory products."